# Urothelial Carcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/urothelial-carcinoma

> 8 upcoming FDA catalysts in urothelial Carcinoma: disitamab vedotin (PFE) on Dec 2026 to Mar 2027 (topline data readout); disitamab vedotin (PFE) on December 2026 (primary completion); disitamab vedotin (PFE) on Jan to Apr 2027 (topline data readout); disitamab vedotin (PFE) on January 2027 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2026 to Mar 2027 | [Disitamab vedotin topline data readout](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04879329)) |
| December 2026 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04879329)) |
| Jan to Apr 2027 | [Disitamab vedotin topline data readout](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT05911295 (Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911295)) |
| January 2027 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT05911295 (Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911295)) |
| March 2027 | [Livmoniplimab primary completion](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Urothelial Carcinoma | scheduled | "NCT06632951 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06632951)) |
| Mar to Jun 2027 | [Livmoniplimab topline data readout](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Urothelial Carcinoma | scheduled | "NCT06632951 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06632951)) |
| Jun to Sep 2027 | [TEVIMBRA® (tislelizumab) topline data readout](https://sec-api.dev/pdufa/tislelizumab) | ONC | Urothelial Carcinoma | scheduled | "NCT03967977 (Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03967977)) |
| June 2027 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Urothelial Carcinoma | scheduled | "NCT03967977 (Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03967977)) |

## Drugs

- [Disitamab vedotin](https://sec-api.dev/pdufa/disitamab-vedotin) (PFE)
- [Livmoniplimab](https://sec-api.dev/pdufa/livmoniplimab) (ABBV)
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/urothelial-carcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Urothelial Carcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/urothelial-carcinoma

```bibtex
@misc{secapidev_indications_urothelial_carcinoma_20261116,
  title        = {Urothelial Carcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/urothelial-carcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_urothelial_carcinoma_20261116","title":"Urothelial Carcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/urothelial-carcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
